Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.

Slides:

Advertisements

Similar presentations

FDA Workshop “Data and Data Needs to Advance Risk Assessment for Emerging Infectious Diseases for Blood and Blood Products” November 29, 2011, Gaithersburg.

Advertisements

Bovine Spongiform Encephalopathy (BSE) in Canada Pedro Piccardo, MD Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research.

A Comparison of Methods for Estimating Child Maltreatment Rates: Evaluation Approaches for a Child Maltreatment Prevention Initiative.

Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.

1 Donor Deferral / Ineligibility for Time Spent in Saudi Arabia to Reduce Risk of vCJD Transmitted by Blood and Blood Products and by Human Cells, Tissues.

Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.

Dengue Transfusion Risk Model Lyle R. Petersen, MD, MPH Brad Biggerstaff, PhD Division of Vector-Borne Diseases Centers for Disease Control and Prevention.

Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:

FDA Transmissible Spongiform Encephalopathies Advisory Committee 23 rd Meeting 01 August 2011 Gaithersburg MD Donor Deferral/Ineligibility for Time Spent.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Presumptive Transfusion Transmissions of vCJD: Introduction to Consideration of Current FDA-recommended Safeguards FDA TSE Advisory Committee 16 th Meeting.

Transfusion Transmission of HIV 1. Past & Current Risk Estimates of Transfusion-Transmitted HIV Infection 2. Layers of Safety in Protection of the Blood.

Current standards, donor safety, and blood supply

Dengue Virus and Its Risk to the U.S. Blood Supply

1 Babesia BPAC: FDA Perspective Sanjai Kumar, PhD Division of Emerging and Transfusion- Transmitted Diseases Office of Blood Research and Review CBER,

CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.

Workshop Summary FDA Workshop on Testing for malarial Infections in Blood Donors Sanjai Kumar, Ph.D. Center for Biologics Evaluation and Research Food.

Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.

Transmissible Spongiform Encephalopathies Advisory Committee 23 rd Meeting Gaithersburg, MD – August 1, 2011 CJD and vCJD Donor Policies: Blood and Blood.

Canadian and U.S. BSE Risk Steven Anderson, Ph.D, MPP Office of Biostatistics & Epidemiology Center for Biologics Evaluation & Research U.S. Food & Drug.

Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.

Draft Guidance: Collection of Platelets by Automated Methods Comments to the Docket and Questions for the Committee Alan E. Williams, Ph.D. Director,

Donor Selection Criteria Dr. Mindy Goldman Transfusion Medicine Residents May 24, 2011.

CBER Hemoglobin/Hematocrit Acceptance Standards and Interdonation Interval in Blood Donors Summary and Questions for the Committee Blood Products Advisory.

Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.

21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?

FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.

FDA Blood Products Advisory Committee Meeting 03 August 2011 Gaithersburg MD Summary of Transmissible Spongiform Advisory Committee Meeting 01 August 2011.

FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.

IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.

Development of FDA Recommendations for deferral of donors based on risk of BSE exposure Alan E. Williams, Ph.D. Director, Division of Blood Applications.

Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.

Parvovirus B19 NAT Screening and Infectivity Mei-ying W Yu CBER/FDA SoGAT XVI Paul Ehrlich Institut July 03, 2003.

Bovine-derived Products Used in the Manufacture and Formulation of Vaccines and Allergenic Products: Minimizing TSE Risks William M. Egan, Ph.D. Acting.

FVIII PRODUCT USAGE IN CLINICAL SETTINGS TSEAC October 31, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER, FDA.

Apheresis Blood Components

Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

1 U.S. vCJD Donor Screening: Human Cells, Tissues, and Cellular and Tissue- Based Products (HCT/Ps) Melissa A Greenwald, MD CAPT, U.S. Public Health Service.

Some Observations on the Deferral of Volunteer Blood Donors for nvCJD Risk Merlyn H. Sayers, M.B., B.Ch., Ph.D. Carter BloodCare Dallas/Fort Worth, Texas.

CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.

Risk Assessments: Models for Estimating the Risk of Transmitting TSE by Human Tissue Intended for Transplantation Rolf E. Taffs, Ph.D. Center for Biologics.

American Red Cross, vCJD Donor Deferral Criteria, and Blood Supply Peter L. Page, MD Senior Medical Officer Biomedical Headquarters TSEAC 06/27/02.

Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.

Blood Center Experience with Double Red Cell Collections by Apheresis: Adverse Events and Impact on Capacity Brian Custer, Hany Kamel, Marj Bravo Peter.

Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.

TSE Clearance in Plasma Derivatives TSE Advisory Committee February 8, 2005 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.

Variant Creutzfeldt-Jakob Disease Impact on U.S. Military Service Members Lt. Col. David Lincoln Deputy Director Armed Services Blood Program Office Unclassified.

RISK COMMUNICATION APPROACH TSEAC 15 December 2006 Mark Weinstein, Ph.D. FDA, Center for Biologics Evaluation and Research.

Modeling Risk of vCJD in US Donors – Residual Risk and Efficiency of Donor Deferral Alan E. Williams, Ph.D. Director, Division of Blood Applications Office.

Hong Yang, Ph.D. Office of Biostatistics and Epidemiology FDA-Center for Biologics Evaluation & Research Transmissible Spongiform Encephalopathies Advisory.

Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;

BSE: World update FDA TSE Advisory Committee Gaithersburg, MD September 18, 2006 Lisa A. Ferguson, DVM Senior Staff Veterinarian USDA, APHIS, Veterinary.

Preliminary Risk Assessment Model for U.S. Plasma Derivatives and vCJD Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center for Biologics.

HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.

Risk Assessment: Questions to the Committee 1.What estimate(s) should be used to reflect the prevalence of vCJD in the U.K.? Proposal: We propose using.

Summary Report and Recommendations on Prescription Drugs: Misuse, Abuse and Dependency Presentation for the County Alcohol and Drug Program Administrators’

American Red Cross: Evolution of vCJD Donor Deferral Criteria and Blood Supply Peter L. Page, MD Senior Medical Officer Biomedical Headquarters TSEAC February.

Identification and Deferral of Tissue Donors for Possible BSE/vCJ-D Exposure: Estimating the Impact Alan E. Williams, Ph.D. Director, Division of Blood.

VCJD World situation and Updates RG Will National CJD Research and Surveillance Unit Edinburgh, UK TSEAC meeting 1 st August 2011.

Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.

Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,

David M. Asher, MD Division of Emerging & Transfusion-Transmitted Diseases Office of Blood Research & Review Center for Biologics Evaluation & Research.

Slide 1 "CJD Lookback Study" (Research Study to Assess the Risk of Blood Borne Transmission of CJD) American Red Cross Blood Services TSEAC October 14,

FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.

1 Update on Study to Further Define the Incidence of T. cruzi Infection in the US Blood Donor Population Susan L. Stramer, PhD American Red Cross BPAC.

TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,

Transfusion Related Acute Lung Injury (TRALI)

FDA’s vCJD Risk Communication on US Plasma- Derived Factor VIII and UK Plasma-Derived Factor XI BPAC April 27, 2007 Mark Weinstein, Ph.D. FDA, Center for.

Bad Blood? An Investigation of the MSM Ban on Blood Donation Lauren Lacy Abstract In 1983, the Food and Drug Administration (FDA), responding to the AIDS.

CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.

Presentation transcript:

Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications Office of Blood Research and Review CBER, FDA TSE Advisory Committee February 8, 2005

Current FDA Recommendations: vCJD –Related Donor Deferral Guidance to Industry January, 2002 > 3 months residence/travel in U.K > 5 years residence/travel in Europe  For donors of Source Plasma this criterion applies only to France (5-10% consumption of UK beef) > 6 months on certain US military bases in Europe between or (up to 35% UK beef consumed) Transfusion in the U.K – present Receipt of bovine insulin sourced in the U.K. after 1980

TSEAC October 14, 2004 Review of current FDA recommendations regarding vCJD-related donor eligibility No TSEAC recommendations for further FDA actions to protect the blood supply Discussion: –Predictive value of donor questions to exclude TSE risk –Feasibility of deferral for history of transfusion outside of the UK

Predictive value of the donor questionnaire Limited data. True validation of donor screening process is complex/expensive DH Task Force - Major progress to improve and streamline the donor questionnaire from a design and cognitive understanding standpoint

Estimates of false negative donor responses derived from post-donation research studies Anonymous REDS mail surveys post-donation demonstrated 2 – 3 % overall “deferrable risk” (0.1 – 0. 5% for individual behavioral risks; higher for less-well- defined exposures) JAMA (12): Parallel findings from other similarly-designed studies (Canada, Hong Kong) Numerous studies based on post-donation interviews of test-positive donors show a high prevalence of deferrable risk

Post Donation Information (PDI) linked to Biological Product Deviation Reports Biological Product Deviation Reports (BPDR) –Reported to FDA only when implicated product was issued. (May substantially underestimate true incidence of actual deviations in some situations) –PDI – most common Biological Product Deviation Report (BPDR) –vCJD travel was most common PDI reported in FY ‘03

Post Donation Information (PDI) linked to Biological Product Deviation Reports Source of PDI* –Subsequent donation – 92% –Telephone call from donor – 4.2% –Third party (e.g., doctor, family member – 3.8% When deferral was known by donor* –Known at time of donation but not provided – 91.8% –Not known at time of donation – 8.1%

BPDRs for Blood and Plasma Donor Centers FYBPDRsPDIsPDIs due to vCJD Travel #%#% FY0123,36318, , FY0232,16223,162723, FY0338,99430, , FY0436,23826, ,

Summary – Predictive value of donor screening Estimates of the predictive value of donor screening are crude, however based upon available data, false negative self-report of donor eligibility may be in ~ 3-5% range of donors deferred on-site, and may be higher in relation to complex questions

Donor Deferrals for History of Transfusion Current FDA recommendation is deferral for transfusion in the U.K. (1980 – present) Recent developments: Probable vCJD transmissions by transfusion Prior donations by vCJD case in France Donor deferral for any previous transfusion –France – 1998 –The Netherlands – 2004 (est 8% donor loss)

Range of possible policy extensions Transfusion in France since 1980 Transfusion in any BSE country in Europe since 1980 Any transfusion since 1980

Estimated Donor Loss Related to History of Transfusion in UK and France Hx tx (UK - deferral already accomplished) 0.4 x 0.05 = 2/10,000 Hx Tx (France) 0.4 x 0.7 x 0.05 = 1.4/10,0000 (Source Plasma donor impact expected to be less due to younger age) Assumptions: – 5% prevalence of transfusion in US donors overall (REDS data) – >/= 5 yr travel/residence CONSERVATIVELY approximates lifetime transfusion exposure (4/10,000 donors have > 5 year UK exposure) –rate of tx among long term residents/travelers to Europe and UK = overall US donor prevalence –prevalence of travel to France = 0.7 x travel to UK

Estimated Donor Loss Related to Deferral for a History of Transfusion in Europe Hx Tx (any Europe, excl. UK) 0.7% x 0.05 = 3/10,000 (Source Plasma donor impact expected to be less due to younger age) Assumptions: – 5% prevalence of transfusion in US donors overall (REDS data) – >/= 5 yr travel/residence CONSERVATIVELY approximates lifetime transfusion exposure (7/10,000 donors reported > 5 year exposure in non-UK Europe) –rate of tx among long term residents/travelers to Europe = overall US donor prevalence

The Euroblood program Began in the early 1970’s At its peak represented one third of the New York area RBC supply and approximately 2.0 % of the total US RBC supply Over 200 New York Metropolitan-area hospitals supplied with Euroblood over the 30 year period of importation (est. >4 million components )

The Euroblood Program In the absence of a massive lookback effort, Euroblood recipients currently living in the US are largely untraceable. The Euroblood program ended in the months prior to the 10/31/02 implementation of FDA deferral recommendations (Phase II)

Questions for the Committee

Question 1. Based upon the available scientific information, does the committee recommend deferral of blood donors transfused since 1980 a. In France? b. In other BSE countries of Europe?

Question 2. Based upon the available scientific information, does the committee recommend deferral of Source Plasma donors transfused since 1980 a. In France? b. In other BSE countries of Europe?